Quoin Pharmaceuticals (QNRX) Institutional Ownership $0.24 -0.04 (-15.16%) Closing price 03/28/2025 03:58 PM EasternExtended Trading$0.25 +0.01 (+2.56%) As of 03/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Quoin Pharmaceuticals (NASDAQ:QNRX)CurrentInstitutional OwnershipPercentage8.63%Number ofInstitutional Buyers(last 12 months)5TotalInstitutional Inflows(last 12 months)$378.91KNumber ofInstitutional Sellers(last 12 months)0 Get QNRX Insider Trade Alerts Want to know when executives and insiders are buying or selling Quoin Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data QNRX Institutional Buying and Selling by Quarter Remove Ads Quoin Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/14/2025 Boothbay Fund Management LLC80,712$53K0.0%N/A1.598% 2/14/2025 Altium Capital Management LLC282,249$184K0.1%N/A5.589% 2/13/2025 Renaissance Technologies LLC133,122$87K0.0%+244.1%2.636% 1/28/2025 Apollon Wealth Management LLC80,025$52K0.0%N/A1.585% 5/20/2024 Virtu Financial LLC30,749$29K0.0%N/A0.773% 5/1/2023 Virtu Financial LLC147,907$70K0.0%N/A3.050% 11/7/2022 Virtu Financial LLC29,865$67K0.0%N/A2.948% (Data available from 1/1/2016 forward)Remove Ads QNRX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of QNRX shares? During the previous two years, the following institutional investors and hedge funds held shares of Quoin Pharmaceuticals shares: Altium Capital Management LLC ($184K), Renaissance Technologies LLC ($87K), Boothbay Fund Management LLC ($53K), and Apollon Wealth Management LLC ($52K), Virtu Financial LLC ($29K).Learn more on QNRX's institutional investors. What percentage of Quoin Pharmaceuticals stock is owned by institutional investors? 8.63% of Quoin Pharmaceuticals stock is owned by institutional investors. Learn more on QNRX's institutional investor holdings. Which institutional investors have been buying Quoin Pharmaceuticals stock? The following institutional investors have purchased Quoin Pharmaceuticals stock in the last 24 months: Altium Capital Management LLC ($282.25K), Virtu Financial LLC ($178.66K), Renaissance Technologies LLC ($94.43K), Boothbay Fund Management LLC ($80.71K), and Apollon Wealth Management LLC ($80.03K). How much institutional buying is happening at Quoin Pharmaceuticals? Institutional investors have bought a total of 716,073 shares in the last 24 months. This purchase volume represents approximately $1.22M in transactions. Related Companies BLAC Institutional Ownership AEMD Institutional Ownership CTCX Institutional Ownership NUWE Institutional Ownership AMIX Institutional Ownership SINT Institutional Ownership GCTK Institutional Ownership TNON Institutional Ownership PSTV Institutional Ownership TTOO Institutional Ownership This page (NASDAQ:QNRX) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredHuge Elon-backed AI rollout begins – buy these nine stocksIf you suspect Elon Musk has an ulterior motive for coming to Washington, D.C.... You're 100% correct. ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quoin Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quoin Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
